Avidia: Shrinking the 4-G space

Though it is joining a space that is occupied by a growing class of fourth-generation antibody companies, Avidia believes its scaffold evolution capabilities will make products that are more diverse and more easily manufactured than those generated by competing platforms. In addition, the company says it is pursuing different targets than new-generation antibody companies.

Avidia has boiled down the starting point for its compounds to 4.5 kD domains of proteins from an

Read the full 727 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE